Form 8-K · Current report
Aflac 8-K, filed Aug 6, 2026
- Filed
- CIK
- 0000004977
- Accession no.
- 0001628280-26-054333
Summary
Aflac reported 2026 second-quarter total revenues of $4.1 billion, down 1.0% year over year, net earnings of $825 million, or $1.63 per diluted share, and adjusted earnings of $883 million, or $1.75 per diluted share, and declared its third-quarter dividend. CEO Daniel P. Amos said the results reflected execution of the company's strategy and cited new product opportunities in Japan and a focus on supplemental health in the U.S.
Key points
- Aflac's second-quarter net earnings rose to $825 million from $599 million a year earlier, while adjusted earnings fell 7.7% to $883 million.
- Aflac returned $1.3 billion to shareholders in the quarter, consisting of $983 million in share repurchases and $309 million in dividends.
- Aflac Japan's pretax adjusted earnings rose 3.4% in yen to ¥118.2 billion, while total new annualized premium sales fell 5.6% to ¥19.6 billion.
- Aflac U.S. net earned premiums rose 2.3% to $1.5 billion, while pretax adjusted earnings fell 4.6% to $370 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Aflac Incorporated (the "Company") issued a press release dated August 6, 2026 in which it reported the Company's 2026 second quarter financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. In addition, a copy of the Company's second quarter supplemental earnings materials is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Item 7.01 Regulation FD Disclosure. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.